Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ucb S.A. (OP: UCBJF )

174.00 UNCHANGED
Last Price Updated: 12:02 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 123
Open 174.00
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 174.00
Today's Range 174.00 - 174.00
52wk Range 73.54 - 194.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. 
Via Benzinga
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+74.00%
+74.00%
1 Month
-10.66%
-10.66%
3 Month
-2.03%
-2.03%
6 Month
+16.12%
+16.12%
1 Year
+136.60%
+136.60%

More News

Read More
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
Via Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Via Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Via Benzinga
Exposures Product Safety
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
Via Benzinga
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
Via Benzinga
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Via Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Via Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Via Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
Via Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Via Benzinga
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
Via Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
Via Benzinga
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Via Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.